Publication at Faculty of Medicine in Hradec Králové |
2021
Abstract
Inclisiran is o novel lipid-lowering drug utilizing synthetic siRNA that inhibits the hepatic production of PCSK9. I t is the first representative of an innovative concept of treating elevated levels of low-density lipoprotein cholesterol (LDL-C).
The efficacy and safety of treatment with inclisiran is assessed in the ORION program of clinical trials.